Search

everythinglearnresearchcommunity

for

Search:↓

Hair growth caps and helmets using low-level laser therapy (LLLT) show potential for treating androgenetic alopecia, but more research is needed. Users often combine these devices with treatments like minoxidil and finasteride for better results.

A user is organizing a group buy for various compounds aimed at reversing hair loss and gray hair, and improving brain health and fat loss. The user has developed a treatment plan based on extensive research and is inviting others to participate, with the option to choose only the compounds they need.

HMI-115 shows promising hair growth and thickening in just 2 months. Results are positive but need more time for confirmation.

Clascoterone (Breezula) showed positive results for treating hair loss without affecting cortisol levels. Opinions vary, with some users optimistic about its potential and others critical of its effectiveness compared to existing treatments like finasteride.

A female user's experience using Spironolactone to treat Female Pattern Hair Loss (FPHL) and Androgenic Alopecia, as well as discussing the effectiveness of the drug at different dosages.

The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.

The user shared their experience with dutasteride for hair loss prevention, noting side effects like muscle weakness and brain fog, and observed increased testosterone levels. They recommend starting with a low dose and adjusting based on individual needs and blood work results.

Hair loss discussion includes Amplifica, a new treatment by Dr. Rassman and Dr. Plikus using molecules from hairy moles. No progress updates mentioned.

User seeks availability of Breezula and its delayed trials. Asks for success with similar topical antiandrogens like fluridil.

Pyrilutamide, a potential topical treatment for male pattern baldness, and the user's anticipation of its Phase 2 trial results. Several users discussed their experiences with Finasteride and RU58841, while others voiced skepticism about the efficacy of Pyrilutamide.

PP405 shows promise in hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil, with significant results in just four weeks. The treatment is still in early stages, with further trials needed to determine its long-term effectiveness and optimal dosage.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.

Experimenting with the effects of creatine and finasteride on DHT levels, as well as a discussion regarding the potential link between creatine supplementation and hair loss.

PP405 shows significantly better early-stage hair regrowth results compared to minoxidil and finasteride, with 31% of users experiencing over 20% density increase in 4–8 weeks. Minoxidil and finasteride show minimal or no visible regrowth in the same timeframe.

The conversation discusses the HMI-115 trial for hair loss, which was expected to end around July 2023 due to a late participant. Participants also mention Minoxidil, finasteride, and RU58841 as treatments.

New product Tomorrowlabs HSF targets hair loss through HIF pathway indirectly by removing scalp iron. Minoxidil and Stemoxydine also relate to HIF pathway.

Discussing results, side effects and potential sources of pyrilutamide for hair loss treatment alongside RU58841 and other treatments such as Minoxidil and finasteride.

Laser caps are found to be more effective than 5% minoxidil for treating hair loss, and when combined with minoxidil, they are even more effective. Some users report positive results with laser treatments, while others see no change; the devices are FDA approved, but opinions on their efficacy vary.

The conversation is about comparing the effectiveness of 5% RU58841 and 0.5% pyrilutamide for hair loss treatment. The user is asking if the higher concentration of RU58841 makes it stronger than the lower dose of pyrilutamide.

The user felt pressured during a hair transplant consultation at Bosley, where they were advised to undergo FUT surgery and use a laser cap for maintenance, but did not meet with a doctor. Other users recommended seeking a second opinion from reputable doctors like Dr. Rassman and suggested trying finasteride first.

The conversation discusses using latanoprost for hair loss treatment. Participants also mention Minoxidil, finasteride, and RU58841 as other treatments.

Finasteride is not linked to a 60% risk of persistent sexual dysfunction; this figure applies only to those already experiencing sexual issues. Most users do not have side effects, and the study's methodology is criticized for selection bias.

RU58841 lacks FDA approval due to financial and safety concerns, including potential cardiological side effects. The company abandoned further research, and users report adverse effects like heart palpitations and gynecomastia.

Recruitment for a verteporfin trial and a separate hair cloning trial using verteporfin and other methods is underway, with locations in Jordan, NYC, Beverly Hills, and Memphis. Dr. Bloxham is conducting the hair cloning trial, and interested participants are encouraged to contact him directly.

A user speculates that a fast metabolism might affect the effectiveness of dutasteride for hair loss. Another user argues that drug response is unrelated to metabolism speed.

User tried various hair loss treatments with limited success. RU58841 was effective but caused side effects, now trying Eucapil and continuing Finasteride.

The conversation discusses the potential updates on the pp405 trial for hair loss, with completion expected by December 2025. Participants express skepticism about new treatments, suggesting continued use of finasteride, while others hope for innovative solutions beyond current medications.

The conversation discusses using very low dose topical finasteride to achieve specific serum DHT reduction percentages. It concludes that finasteride dosage increases linearly between 5-30% DHT reduction but requires exponential increases for reductions up to 70%.

TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.